Medium

Five Reasons Illumina Should Fight Roche’s Insulting Low-Ball Bid

Illumina is like the Apple of the genomics business. Tools made by the San Diego company (NASDAQ: ILMN) are revered by genomics researchers around the world just like millions of consumers love their iPhones and iPads. And Illumina holds its dominant position at an enviable moment in history, as we’re heading into a scientific golden age when human genomes will be sequenced for $1,000 or less.
Flag this

Comments

There are currently no comments. Add a new comment!

Post a comment

You must be logged in to post comments. Login now

Posted by Mike Spear

PictureIcon-mod-badge

I am the Communications Director for Genome Alberta and we manage this application. In my past life I was a journalist and manager with the CBC. You can find my genome posted at www.genomealberta.ca

0 people like this

Be the first to like this